MKGAF (Merck KGaA) Other Current Liabilities: $5,084 Mil (As of Mar. 2026)


MKGAF Merck KGaA MKGAF
84 GF Score
Price $164.15
GF Value $159.56
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Other Current Liabilities?

Merck KGaA MKGAF +1.82% 84 Other Current Liabilities is $5,084 Mil as of Mar. 2026. GuruFocus rates MKGAF with a GF Score™ of 84/100 and a GF Value™ of $159.56 (Fairly Valued). The stock has 10 warning signs investors should review.

Merck KGaA's other current liabilities for the quarter that ended in Mar. 2026 was $5,084 Mil.

Merck KGaA's quarterly other current liabilities increased from Sep. 2025 ($4,009 Mil) to Dec. 2025 ($4,525 Mil) and increased from Dec. 2025 ($4,525 Mil) to Mar. 2026 ($5,084 Mil).

Merck KGaA's annual other current liabilities declined from Dec. 2023 ($4,285 Mil) to Dec. 2024 ($4,252 Mil) but then increased from Dec. 2024 ($4,252 Mil) to Dec. 2025 ($4,525 Mil).

Merck KGaA Other Current Liabilities Related Terms

Merck KGaA Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Other Current Liabilities Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,506.22 4,370.76 4,284.63 4,252.36 4,524.59

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,400.00 3,696.66 4,009.39 4,524.59 5,084.39
MKGAF
84GF Score
Merck KGaA MKGAF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $5,084 Mil mean?
Merck KGaA (MKGAF) has a Other Current Liabilities of $5,084 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Merck KGaA.
Is Merck KGaA's Other Current Liabilities too high?
Merck KGaA's current Other Current Liabilities is $5,084 Mil. Overall, Merck KGaA has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Other Current Liabilities compare to ZTS and UTHR?
Merck KGaA's Other Current Liabilities of $5,084 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Merck KGaA. Merck KGaA's current Other Current Liabilities is $5,084 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MKGAF) is currently considered Fairly Valued. The stock's GF Value™ is $159.56, compared to a current price of $164.15 — trading 2.9% above its estimated fair value. The current Other Current Liabilities is $5,084 Mil. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Merck KGaA (MKGAF), the current Other Current Liabilities is $5,084 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of $164.15 is trading 2.9% above its estimated GF Value™ of $159.56. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Other Current Liabilities: $5,084 Mil
  • GF Value™: $159.56 vs. price of $164.15 (2.9% above fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for MKGAF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$164.15
Price
$159.56
GF Value